Seamless Therapeutics
Cambridge, United States· Est.
Programmable recombinase gene editing platform for large, precise DNA insertions without CRISPR-style repair. Eli Lilly deal for hearing loss worth $1.12bn+ in milestones.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
About
Programmable recombinase gene editing platform for large, precise DNA insertions without CRISPR-style repair. Eli Lilly deal for hearing loss worth $1.12bn+ in milestones.
Gene Therapy